

# Pathoanatomy of Parkinson's disease

Journal of Neurology

247, II3-II10

DOI: [10.1007/pl00007758](https://doi.org/10.1007/pl00007758)

Citation Report

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Is there neuroprotection in Parkinson syndrome?. Journal of Neurology, 2000, 247, IV8-IV11.  | 1.8 | 6         |
| 2  | Lack of Nigral Pathology in Transgenic Mice Expressing Human $\alpha$ -Synuclein Driven by the Tyrosine Hydroxylase Promoter. Neurobiology of Disease, 2001, 8, 535-539.   | 2.1 | 273       |
| 3  | Distribution and Modulation of Histamine H3 Receptors in Basal Ganglia and Frontal Cortex of Healthy Controls and Patients with Parkinson's Disease. Neurobiology of Disease, 2001, 8, 707-716.  | 2.1 | 105       |
| 4  | Nerve cells expressing heat-shock proteins in Parkinson's disease. Acta Neuropathologica, 2001, 102, 449-454.  | 3.9 | 53        |
| 5  | Advances in genetic models of Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 456-466.   | 0.8 | 8         |
| 6  | Alzheimer Disease: Evaluation of a Functional MR Imaging Index as a Marker. Radiology, 2002, 225, 253-259.   | 3.6 | 268       |
| 7  | Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of $\alpha$ -Synuclein in the Nigrostriatal System. Journal of Neuroscience, 2002, 22, 2780-2791.  | 1.7 | 633       |
| 8  | Dopamine Modulates the Response of the Human Amygdala: A Study in Parkinson's Disease. Journal of Neuroscience, 2002, 22, 9099-9103.   | 1.7 | 261       |
| 9  | Early defect in the expression of mouse sperm DnaJ 1, a member of the DNAJ/heat shock protein 40 chaperone protein family, in the spinal cord of the wobbler mouse, a murine model of motoneuronal degeneration. Neuroscience, 2002, 113, 825-835. | 1.1 | 20        |
| 10 | Models of repair mechanisms for future treatment modalities of Parkinson's disease. Brain Research Bulletin, 2002, 57, 839-846.  | 1.4 | 25        |
| 11 | Chapter 9 Innervation of the small intestine. Biology of Growing Animals, 2002, 1, 235-270.  | 0.3 | 7         |
| 12 | Spatial Working Memory and the Brainstem Cholinergic Innervation to the Anterior Thalamus. Journal of Neuroscience, 2002, 22, 1922-1928.   | 1.7 | 50        |
| 13 | Impaired fear conditioning in Alzheimer's disease. Neuropsychologia, 2002, 40, 1187-1195.  | 0.7 | 112       |
| 14 | Nerve growth factor levels in parkinson disease and experimental parkinsonian rats. Brain Research, 2002, 952, 122-127.  | 1.1 | 58        |
| 15 | Early diagnosis of Parkinson's disease. Journal of Neurology, 2002, 249, 1-1.  | 1.8 | 74        |
| 16 | Parkinson syndrome as a manifestation of mitochondriopathy. Acta Neurologica Scandinavica, 2002, 105, 384-389.   | 1.0 | 16        |
| 17 | Effects of Coenzyme Q10 in Early Parkinson Disease. Archives of Neurology, 2002, 59, 1541.   | 4.9 | 994       |
| 18 | The Wobbler Mouse: A Neurodegeneration Jigsaw Puzzle. Molecular Neurobiology, 2003, 28, 65-106.  | 1.9 | 55        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | EPIDEMIOLOGY OF NEURODEGENERATION. Annual Review of Neuroscience, 2003, 26, 81-104.   | 5.0 | 451       |
| 20 | Effects of Coenzyme Q <sub>10</sub> in Huntington's disease and early Parkinson's disease. BioFactors, 2003, 18, 153-161.   | 2.6 | 56        |
| 21 | Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission, 2003, 110, 517-536.  | 1.4 | 1,323     |
| 22 | Dopamine receptor agonists differ in their actions on cardiac ion channels. European Journal of Pharmacology, 2003, 482, 31-37.   | 1.7 | 23        |
| 23 | Prevalence of amyloid- $\beta$ deposition in the cerebral cortex in Parkinson's disease. Movement Disorders, 2003, 18, 81-86.   | 2.2 | 73        |
| 24 | Coordinate transcriptional regulation of dopamine synthesis genes by $\alpha$ -synuclein in human neuroblastoma cell lines. Journal of Neurochemistry, 2003, 85, 957-968.                       | 2.1 | 143       |
| 25 | Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental Neurology, 2003, 184, 68-79.  | 2.0 | 166       |
| 26 | The neurobiology and control of anxious states. Progress in Neurobiology, 2003, 70, 83-244.   | 2.8 | 815       |
| 27 | Pramipexole in Routine Clinical Practice. CNS Drugs, 2003, 17, 965-973.   | 2.7 | 74        |
| 28 | Investigation of Supervisory Attentional System Functions in Patients With Parkinson's Disease Using the Hayling Task. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 751-760. | 0.8 | 41        |
| 29 | Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Human Molecular Genetics, 2003, 12, 2599-2608.                  | 1.4 | 131       |
| 30 | Treatments of Parkinson Disease. Archives of Neurology, 2003, 60, 1680.   | 4.9 | 19        |
| 31 | On-line motor control in patients with Parkinson's disease. Brain, 2004, 127, 1755-1773.  | 3.7 | 86        |
| 32 | The Flavonoid Baicalein Inhibits Fibrillation of $\alpha$ -Synuclein and Disaggregates Existing Fibrils. Journal of Biological Chemistry, 2004, 279, 26846-26857.                               | 1.6 | 416       |
| 33 | A New Rat Model of the Human Serial Reaction Time Task: Contrasting Effects of Caudate and Hippocampal Lesions. Journal of Neuroscience, 2004, 24, 1034-1039.                                   | 1.7 | 37        |
| 34 | Could a loss of $\alpha$ -synuclein function put dopaminergic neurons at risk?. Journal of Neurochemistry, 2004, 89, 1318-1324.   | 2.1 | 130       |
| 35 | Increased dopamine release in vivo by estradiol benzoate from the central amygdaloid nucleus of Parkinson's disease model rats. Journal of Neurochemistry, 2004, 90, 654-658.                   | 2.1 | 26        |
| 36 | The basal ganglia network mediates the planning of movement amplitude. European Journal of Neuroscience, 2004, 19, 2871-2880.   | 1.2 | 90        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Neuroimaging of Parkinson's disease and atypical parkinsonism. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 284-289.  | 2.0 | 4         |
| 38 | Idiopathic hyposmia as a preclinical sign of Parkinson's disease. <i>Annals of Neurology</i> , 2004, 56, 173-181.   | 2.8 | 672       |
| 39 | Variable effects of chronic subcutaneous administration of rotenone on striatal histology. <i>Journal of Comparative Neurology</i> , 2004, 478, 418-426.                                    | 0.9 | 86        |
| 40 | Alteration in $\alpha$ -synuclein mRNA expression in Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 162-170.  | 2.2 | 111       |
| 41 | Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 649-655.   | 2.2 | 33        |
| 42 | Cell therapy in Parkinson's disease. <i>NeuroRx</i> , 2004, 1, 382-393.   | 6.0 | 331       |
| 43 | Parkinson's Disease Without Expected Neuropathologic Abnormality. <i>Journal of the American Medical Directors Association</i> , 2004, 5, 407-409.  | 1.2 | 2         |
| 44 | Mitochondrial dysfunction and possible treatments in Parkinson's disease—a review. <i>Mitochondrion</i> , 2004, 4, 641-648.   | 1.6 | 37        |
| 45 | RBANS analysis of verbal memory in multiple sclerosis. <i>Archives of Clinical Neuropsychology</i> , 2004, 19, 825-834.   | 0.3 | 45        |
| 46 | Does cellular iron dysregulation play a causative role in Parkinson's disease?. <i>Ageing Research Reviews</i> , 2004, 3, 327-343.  | 5.0 | 110       |
| 47 | Viral Vector Mediated Overexpression of Human $\alpha$ -Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease. <i>CNS Spectrums</i> , 2005, 10, 235-244. | 0.7 | 31        |
| 48 | Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice. <i>Journal of Biological Chemistry</i> , 2005, 280, 21418-21426.   | 1.6 | 221       |
| 49 | The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. <i>Journal of Neurochemistry</i> , 2005, 95, 930-939.   | 2.1 | 183       |
| 50 | $\alpha$ -Synuclein pathology does not predict extrapyramidal symptoms or dementia. <i>Annals of Neurology</i> , 2005, 57, 82-91.   | 2.8 | 287       |
| 51 | Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 271-282.                                     | 2.2 | 79        |
| 52 | Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. <i>Movement Disorders</i> , 2005, 20, 540-544.  | 2.2 | 129       |
| 54 | Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. <i>Journal of Neurology</i> , 2005, 252, 1345-1352.                             | 1.8 | 129       |
| 55 | Determinants of autonomic dysfunction in idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2005, 252, 1530-1536.  | 1.8 | 29        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 56 | Increased cell-cell adhesion, a novel effect of R-( $\alpha$ )-deprenyl. <i>Journal of Neural Transmission</i> , 2005, 112, 1433-1445.   | 1.4 | 11        |
| 57 | Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. <i>Neurology</i> , 2005, 64, 224-229.  | 1.5 | 280       |
| 58 | Anhedonia, Depression, and Motor Functioning in Parkinson's Disease During Treatment With Pramipexole. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2005, 17, 214-220.               | 0.9 | 122       |
| 59 | Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. <i>Brain</i> , 2005, 128, 2281-2290.                                    | 3.7 | 116       |
| 60 | Quantitative 1H Magnetic Resonance Spectroscopic Imaging Determines Therapeutic Immunization Efficacy in an Animal Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2005, 25, 1691-1700. | 1.7 | 76        |
| 61 | MPTP Treatment Impairs Tyrosine Hydroxylase Immunopositive Fibers Not Only in the Striatum, but Also in the Amygdala. <i>Neurodegenerative Diseases</i> , 2005, 2, 44-48.                              | 0.8 | 14        |
| 62 | Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 266-270.                   | 0.3 | 118       |
| 63 | Mechanistic Approaches to Parkinson's Disease Pathogenesis. <i>Brain Pathology</i> , 2002, 12, 499-510.  | 2.1 | 115       |
| 64 | Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. <i>Journal of Neurochemistry</i> , 2006, 99, 1188-1196.   | 2.1 | 93        |
| 65 | Deep brain stimulation: Postoperative issues. <i>Movement Disorders</i> , 2006, 21, S219-S237.   | 2.2 | 276       |
| 66 | Testosterone Therapy in Men With Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 729.  | 4.9 | 88        |
| 67 | Normalizing motor-related brain activity: Subthalamic nucleus stimulation in Parkinson disease. <i>Neurology</i> , 2006, 66, 1192-1199.  | 1.5 | 143       |
| 68 | Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 742-745.          | 0.9 | 63        |
| 69 | Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation. <i>Neurology</i> , 2007, 69, 1580-1584.   | 1.5 | 28        |
| 70 | Dopamine effects on identified rat vagal motoneurons. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G1002-G1008.   | 1.6 | 29        |
| 71 | Dysfunctional Facial Emotional Expression and Comprehension in a Patient with Corticobasal Degeneration. <i>Neurocase</i> , 2007, 13, 165-168.   | 0.2 | 22        |
| 72 | Genetics of Parkinson disease. <i>Genetics in Medicine</i> , 2007, 9, 801-811.   | 1.1 | 101       |
| 73 | Axial Signs and Magnetic Resonance Imaging Correlates in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2007, 34, 56-61.  | 0.3 | 40        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 74 | Deep brain stimulation in neurologic disorders. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 1-16.   | 1.1 | 112       |
| 75 | DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents. <i>Physiology and Behavior</i> , 2007, 92, 46-53.  | 1.0 | 21        |
| 76 | Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult. <i>Neuroscience</i> , 2007, 147, 592-598.  | 1.1 | 20        |
| 77 | Dementia with Lewy Bodies. <i>Neurologic Clinics</i> , 2007, 25, 741-760.   | 0.8 | 59        |
| 78 | Asymmetry in the emotional content of lateralised multimodal hallucinations following right thalamic stroke. <i>Cognitive Neuropsychiatry</i> , 2007, 12, 422-436.  | 0.7 | 5         |
| 80 | Depression symptoms in movement disorders: Comparing Parkinson's disease, dystonia, and essential tremor. <i>Movement Disorders</i> , 2007, 22, 666-672.  | 2.2 | 116       |
| 82 | Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. <i>Journal of Neural Transmission</i> , 2008, 115, 1001-1009.   | 1.4 | 217       |
| 83 | Transcriptional regulation of mesencephalic dopaminergic neurons: The full circle of life and death. <i>Movement Disorders</i> , 2008, 23, 319-328.   | 2.2 | 76        |
| 84 | Methamphetamine Fails to Alter the Noradrenergic Integrity of the Heart. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 337-344.   | 1.8 | 9         |
| 85 | Depressive symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 21-25.   | 1.7 | 131       |
| 86 | The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of $\alpha$ -synuclein staging. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 284-295. | 1.8 | 186       |
| 87 | Spreading activation of lexical-semantic networks in Parkinson's disease. <i>Neuropsychologia</i> , 2008, 46, 1908-1914.  | 0.7 | 17        |
| 88 | Telencephalon: Basal Ganglia. , 2008, , 427-489.  |     | 5         |
| 89 | Variability in the clinical expression of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2008, 266, 197-203.  | 0.3 | 64        |
| 90 | Proteome analysis of human substantia nigra in Parkinson's disease. <i>Proteome Science</i> , 2008, 6, 8.   | 0.7 | 137       |
| 91 | Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 505-508.  | 1.1 | 57        |
| 92 | Redox imbalance in Parkinson's disease. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2008, 1780, 1362-1367.  | 1.1 | 232       |
| 93 | Altered Diffusion in the Frontal Lobe in Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2008, 29, 501-505.  | 1.2 | 177       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 94  | Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition. <i>Journal of Neuroscience</i> , 2008, 28, 8040-8052.                    | 1.7 | 54        |
| 95  | Testing Basal Ganglia Motor Functions Through Reversible Inactivations in the Posterior Internal Globus Pallidus. <i>Journal of Neurophysiology</i> , 2008, 99, 1057-1076.                  | 0.9 | 98        |
| 96  | Cognitive Characteristics Associated with Mild Cognitive Impairment in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 121-129.                          | 0.7 | 53        |
| 97  | Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys. <i>Human Gene Therapy</i> , 2009, 20, 497-510.   | 1.4 | 77        |
| 98  | Startle reflex hyporeactivity in Parkinson's disease: An emotion-specific or arousal-modulated deficit?. <i>Neuropsychologia</i> , 2009, 47, 1917-1927.                                     | 0.7 | 45        |
| 99  | The morbid anatomy of dementia in Parkinson's disease. <i>Acta Neuropathologica</i> , 2009, 118, 587-598.   | 3.9 | 77        |
| 100 | Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. <i>Journal of Neurochemistry</i> , 2009, 108, 1561-1574.         | 2.1 | 139       |
| 101 | Seeding induced by $\alpha$ -synuclein oligomers provides evidence for spreading of $\alpha$ -synuclein pathology. <i>Journal of Neurochemistry</i> , 2009, 111, 192-203.                   | 2.1 | 254       |
| 102 | The severity of leukoaraiosis correlates with the clinical phenotype of Parkinson's disease. <i>Archives of Gerontology and Geriatrics</i> , 2009, 49, 255-259.                             | 1.4 | 62        |
| 103 | Parkinson's disease: The syndrome, the pathogenesis and pathophysiology. <i>Cortex</i> , 2009, 45, 915-921.   | 1.1 | 139       |
| 104 | Diffusion MRI in Neurological Disorders. , 2009, , 175-203.   |     | 6         |
| 105 | Cyclooxygenase and Neuroinflammation in Parkinson's Disease Neurodegeneration. <i>Current Neuropharmacology</i> , 2010, 8, 62-68.   | 1.4 | 88        |
| 106 | Reduced hypocretin (orexin) levels in dementia with Lewy bodies. <i>NeuroReport</i> , 2010, 21, 756-760.  | 0.6 | 35        |
| 107 | Immediate Effects of Thermal Tactile Stimulation on Timing of Swallow in Idiopathic Parkinson's Disease. <i>Dysphagia</i> , 2010, 25, 207-215.  | 1.0 | 63        |
| 108 | Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of $\alpha$ -Synucleinopathy. <i>PLoS ONE</i> , 2010, 5, e9313.                   | 1.1 | 327       |
| 109 | Alterations in mGluR5 Expression and Signaling in Lewy Body Disease and in Transgenic Models of Alpha-Synucleinopathy – Implications for Excitotoxicity. <i>PLoS ONE</i> , 2010, 5, e14020. | 1.1 | 66        |
| 111 | Characteristics of executive function impairment in Parkinson's disease patients without dementia. <i>Journal of the International Neuropsychological Society</i> , 2010, 16, 268-277.      | 1.2 | 141       |
| 112 | Regional patterns of brain tissue loss associated with depression in Parkinson disease. <i>Neurology</i> , 2010, 75, 857-863.   | 1.5 | 143       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 113 | Viral vector-mediated overexpression of $\alpha$ -synuclein as a progressive model of Parkinson's disease. <i>Progress in Brain Research</i> , 2010, 184, 89-111.  | 0.9  | 99        |
| 114 | Parkin and Parkinson's disease: Differentiated by non-dopaminergic dysfunction?. <i>Experimental Neurology</i> , 2010, 225, 48-50.   | 2.0  | 0         |
| 115 | Predictors of HVOT Performance in Parkinson's Disease. <i>Applied Neuropsychology</i> , 2011, 18, 210-215.   | 1.5  | 5         |
| 116 | Enteric Neuromuscular Pathology Update. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 695-713.  | 1.0  | 1         |
| 117 | The mesopontine rostromedial tegmental nucleus: An integrative modulator of the reward system. <i>Basal Ganglia</i> , 2011, 1, 191-200.  | 0.3  | 50        |
| 118 | Metal attenuating therapies in neurodegenerative disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1717-1745.   | 1.4  | 22        |
| 119 | <i>Basal Ganglia</i> , 2011, , 495-564.  |      | 3         |
| 120 | Increased spreading activation in depression. <i>Brain and Cognition</i> , 2011, 77, 265-270.  | 0.8  | 11        |
| 121 | High-Level Language Production in Parkinson's Disease: A Review. <i>Parkinson's Disease</i> , 2011, 2011, 1-12.  | 0.6  | 68        |
| 122 | Perception of Speech by Individuals with Parkinson's Disease: A Review. <i>Parkinson's Disease</i> , 2011, 2011, 1-11.   | 0.6  | 39        |
| 123 | Gene Therapy for Parkinson's and Alzheimer's Diseases: from the Bench to Clinical Trials. <i>Current Pharmaceutical Design</i> , 2011, 17, 3434-3445.  | 0.9  | 20        |
| 124 | Weight Changes in Subthalamic Nucleus vs Globus Pallidus Internus Deep Brain Stimulation: Results From the COMPARE Parkinson Disease Deep Brain Stimulation Cohort. <i>Neurosurgery</i> , 2011, 68, 1233-1238. | 0.6  | 35        |
| 125 | Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies. <i>Journal of Neurochemistry</i> , 2011, 118, 326-338.                                  | 2.1  | 20        |
| 126 | Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. <i>Journal of Neurochemistry</i> , 2011, 118, 1043-1055.                            | 2.1  | 70        |
| 127 | Color vision in Parkinson's disease and essential tremor. <i>European Journal of Neurology</i> , 2011, 18, 577-583.  | 1.7  | 41        |
| 128 | Treatment of depressive symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 11-15.   | 1.7  | 54        |
| 129 | Parkinson's disease and cancer: two wars, one front. <i>Nature Reviews Cancer</i> , 2011, 11, 813-823.   | 12.8 | 146       |
| 130 | Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions. <i>Neurotoxicity Research</i> , 2011, 19, 211-234.  | 1.3  | 25        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 131 | Focal cortical and subcortical atrophy in early Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 436-441.   | 2.2 | 112       |
| 132 | Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. <i>Movement Disorders</i> , 2011, 26, 901-905.   | 2.2 | 3         |
| 133 | Anhedonia in Parkinson's disease: A systematic review of the literature. <i>Movement Disorders</i> , 2011, 26, 1825-1834.   | 2.2 | 60        |
| 134 | Parkinson's disease induced pluripotent stem cells with triplication of the $\alpha$ -synuclein locus. <i>Nature Communications</i> , 2011, 2, 440.   | 5.8 | 406       |
| 135 | Influence of left versus right hemibody onset Parkinson's disease on cardiovascular control. <i>Laterality</i> , 2011, 16, 164-173.   | 0.5 | 5         |
| 136 | Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human $\alpha$ -Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2012, 32, 1536-1544.   | 1.7 | 84        |
| 137 | D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 543-549.  | 1.0 | 48        |
| 138 | Pathological $\alpha$ -Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. <i>Science</i> , 2012, 338, 949-953.  | 6.0 | 2,024     |
| 139 | Does a prion-like mechanism play a major role in the apparent spread of $\alpha$ -synuclein pathology?. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 48.  | 3.0 | 5         |
| 140 | Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. <i>Progress in Neurobiology</i> , 2012, 98, 222-238.   | 2.8 | 84        |
| 141 | Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression. <i>NeuroToxicology</i> , 2012, 33, 321-331. | 1.4 | 21        |
| 142 | Gene expression in the Parkinson's disease brain. <i>Brain Research Bulletin</i> , 2012, 88, 302-312.   | 1.4 | 42        |
| 143 | Anhedonia in Japanese patients with Parkinson's disease: Analysis using the Snaith's Hamilton Pleasure Scale. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 352-355.  | 0.6 | 19        |
| 144 | Parkinson's Disease. <i>Sub-Cellular Biochemistry</i> , 2012, 65, 389-455.  | 1.0 | 283       |
| 145 | Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1937-1948.  | 3.3 | 49        |
| 146 | Nonuniform Cardiac Denervation Observed by 11C-meta-Hydroxyephedrine PET in 6-OHDA-Treated Monkeys. <i>PLoS ONE</i> , 2012, 7, e35371.  | 1.1 | 22        |
| 147 | Concordant Signaling Pathways Produced by Pesticide Exposure in Mice Correspond to Pathways Identified in Human Parkinson's Disease. <i>PLoS ONE</i> , 2012, 7, e36191.   | 1.1 | 49        |
| 148 | Acetyl-L-Carnitine in Parkinson's Disease. , 2012, , .  |     | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 149 | Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. <i>Human Brain Mapping</i> , 2012, 33, 2521-2534.                                | 1.9 | 184       |
| 150 | Autophagy in Dementias. <i>Brain Pathology</i> , 2012, 22, 99-109.  | 2.1 | 55        |
| 151 | Basal ganglia activity patterns in parkinsonism and computational modeling of their downstream effects. <i>European Journal of Neuroscience</i> , 2012, 36, 2213-2228.  | 1.2 | 101       |
| 152 | Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. <i>Clinical Autonomic Research</i> , 2012, 22, 57-61.  | 1.4 | 33        |
| 153 | The topography of brain damage at different stages of Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 2798-2807.  | 1.9 | 61        |
| 154 | Neuropathologic analysis of Lewy-related $\alpha$ -synucleinopathy in olfactory mucosa. <i>Neuropathology</i> , 2013, 33, 47-58.  | 0.7 | 42        |
| 155 | Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. <i>Journal of the Neurological Sciences</i> , 2013, 332, 21-29.   | 0.3 | 46        |
| 156 | The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.   | 2.4 | 205       |
| 157 | Mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 517-521.   | 1.4 | 14        |
| 158 | Autonomic dysfunction in Parkinson disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 259-278.   | 1.0 | 76        |
| 159 | Diffusion tensor imaging and correlations to Parkinson rating scales. <i>Journal of Neurology</i> , 2013, 260, 2823-2830.   | 1.8 | 42        |
| 160 | Biomarkers, Mechanisms, and Potential Prevention of Catecholamine Neuron Loss in Parkinson Disease. <i>Advances in Pharmacology</i> , 2013, 68, 235-272.  | 1.2 | 28        |
| 161 | Oxidative and nitrative $\alpha$ -synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. <i>Journal of Neurochemistry</i> , 2013, 125, 491-511.           | 2.1 | 116       |
| 162 | The many faces of $\alpha$ -synuclein: from structure and toxicity to therapeutic target. <i>Nature Reviews Neuroscience</i> , 2013, 14, 38-48.   | 4.9 | 1,322     |
| 163 | Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein. <i>NeuroToxicology</i> , 2013, 37, 144-153. | 1.4 | 19        |
| 165 | Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculopontine Nucleus in Parkinson Disease. <i>American Journal of Pathology</i> , 2013, 183, 1826-1840.            | 1.9 | 53        |
| 166 | A review of cognitive and other non-motor problems in Parkinson's disease. <i>Aging Health</i> , 2013, 9, 89-102.   | 0.3 | 0         |
| 167 | Selective Effects of Dopamine Depletion and L-DOPA Therapy on Learning-Related Firing Dynamics of Striatal Neurons. <i>Journal of Neuroscience</i> , 2013, 33, 4782-4795.   | 1.7 | 37        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 168 | Î±-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. <i>Acta Neuropathologica</i> , 2013, 125, 753-769.   | 3.9 | 369       |
| 169 | The contribution of trail making to the prediction of performance-based instrumental activities of daily living in Parkinson's disease without dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 530-539.      | 0.8 | 29        |
| 170 | Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type Î±-Synuclein and Reduces the Pathology in an Î±-Synuclein Model of LBD. <i>Molecular Therapy</i> , 2013, 21, 31-41.   | 3.7 | 65        |
| 171 | Thalamic Projection Fiber Integrity in de novo Parkinson Disease. <i>American Journal of Neuroradiology</i> , 2013, 34, 74-79.   | 1.2 | 48        |
| 172 | Parkinson's Disease: A Complex Interplay of Mitochondrial DNA Alterations and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2388-2409.  | 1.8 | 54        |
| 173 | White matter microstructure deteriorates across cognitive stages in Parkinson disease. <i>Neurology</i> , 2013, 80, 1841-1849.   | 1.5 | 129       |
| 174 | Very low levels of education and cognitive reserve. <i>Neurology</i> , 2013, 81, 650-657.  | 1.5 | 133       |
| 175 | Regional vulnerability of hippocampal subfields and memory deficits in Parkinson's disease. <i>Hippocampus</i> , 2013, 23, 720-728.  | 0.9 | 63        |
| 176 | Working memory in Parkinson's disease: The effects of depression and side of onset of motor symptoms.. <i>Neuropsychology</i> , 2013, 27, 303-313.   | 1.0 | 13        |
| 178 | Sleep disturbances. , 0, , 192-210.  |     | 0         |
| 179 | Automated, High Accuracy Classification of Parkinsonian Disorders: A Pattern Recognition Approach. <i>PLoS ONE</i> , 2013, 8, e69237.  | 1.1 | 39        |
| 180 | Amyloidogenic Protein of Î±-Synuclein. <i>Hanyang Medical Reviews</i> , 2013, 33, 123.   | 0.4 | 1         |
| 181 | Diffusion Tensor Imaging of Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy: A Tract-Based Spatial Statistics Study. <i>PLoS ONE</i> , 2014, 9, e112638.   | 1.1 | 72        |
| 182 | Distribution of nanoparticles throughout the cerebral cortex of rodents and non-human primates: Implications for gene and drug therapy. <i>Frontiers in Neuroanatomy</i> , 2014, 8, 9.   | 0.9 | 37        |
| 183 | Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G1013-G1023. | 1.6 | 44        |
| 184 | Anterior Temporal Atrophy and Posterior Progression in Patients with Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2014, 14, 125-132.   | 0.8 | 22        |
| 185 | Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. <i>Journal of Clinical Movement Disorders</i> , 2014, 1, 8.  | 2.2 | 17        |
| 186 | Iodine-123 Metaiodobenzylguanidine Scintigraphy and Iodine-123 Ioflupane Single Photon Emission Computed Tomography in Lewy Body Diseases: Complementary or Alternative Techniques?. <i>Journal of Neuroimaging</i> , 2014, 24, 149-154.       | 1.0 | 43        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 187 | Mechanisms of Body Weight Fluctuations in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2014, 5, 84.  | 1.1 | 85        |
| 188 | Pathomechanisms and compensatory efforts related to Parkinsonian speech. <i>NeuroImage: Clinical</i> , 2014, 4, 82-97.   | 1.4 | 72        |
| 189 | Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson's Disease. <i>NeuroMolecular Medicine</i> , 2014, 16, 217-230.   | 1.8 | 175       |
| 190 | Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity. <i>NeuroToxicology</i> , 2014, 43, 73-81.   | 1.4 | 40        |
| 191 | Phosphorylated $\alpha$ -synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. <i>Neuroscience Letters</i> , 2014, 571, 34-38.   | 1.0 | 115       |
| 192 | Targeting impulsivity in Parkinson's disease using atomoxetine. <i>Brain</i> , 2014, 137, 1986-1997.   | 3.7 | 116       |
| 193 | Cortical gyrification reductions and subcortical atrophy in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 122-126.  | 2.2 | 44        |
| 194 | Reduced neural connectivity but increased task-related activity during working memory in de novo Parkinson patients. <i>Human Brain Mapping</i> , 2015, 36, 1554-1566.   | 1.9 | 57        |
| 195 | Many Faces of Parkinson's Disease: Non-Motor Symptoms of Parkinson's Disease. <i>Journal of Movement Disorders</i> , 2015, 8, 92-97.   | 0.7 | 109       |
| 196 | shRNA targeting $\alpha$ -synuclein prevents neurodegeneration in a Parkinson's disease model. <i>Journal of Clinical Investigation</i> , 2015, 125, 2721-2735.  | 3.9 | 143       |
| 197 | Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. <i>Frontiers in Neuroanatomy</i> , 2015, 9, 5.   | 0.9 | 153       |
| 198 | Brain region-specific gene expression profiles in freshly isolated rat microglia. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 84.   | 1.8 | 85        |
| 199 | Unexpected Dual Task Benefits on Cycling in Parkinson Disease and Healthy Adults: A Neuro-Behavioral Model. <i>PLoS ONE</i> , 2015, 10, e0125470.  | 1.1 | 20        |
| 200 | Comparison of the structure, function and autophagic maintenance of mitochondria in nigrostriatal and tuberoinfundibular dopamine neurons. <i>Brain Research</i> , 2015, 1622, 240-251.  | 1.1 | 11        |
| 201 | Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 19.  | 3.0 | 11        |
| 202 | Generalized motor inhibitory deficit in Parkinson's disease patients who freeze. <i>Journal of Neural Transmission</i> , 2015, 122, 1693-1701.   | 1.4 | 20        |
| 203 | Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2015, 21, 31.           | 0.8 | 25        |
| 204 | Elevated $\alpha$ -synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells. <i>Cell Death and Disease</i> , 2015, 6, e1994-e1994. | 2.7 | 125       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 205 | Parkin Mutations Reduce the Complexity of Neuronal Processes in iPSC-Derived Human Neurons. <i>Stem Cells</i> , 2015, 33, 68-78.   | 1.4 | 95        |
| 206 | â~NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motorâ€“cognitive impairments in Parkinsonism. <i>Drug and Chemical Toxicology</i> , 2015, 38, 415-427.   | 1.2 | 12        |
| 207 | Imaging changes associated with cognitive abnormalities in Parkinsonâ€™s disease. <i>Brain Structure and Function</i> , 2015, 220, 2249-2261.  | 1.2 | 41        |
| 208 | Parkinsonâ€™s Disease and Cognitive Impairment. <i>Parkinson's Disease</i> , 2016, 2016, 1-8.  | 0.6 | 50        |
| 209 | The Alterations of Cortical Volume, Thickness, Surface, and Density in the Intermediate Sporadic Parkinson's Disease from the Han Population of Mainland China. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 185.   | 1.7 | 7         |
| 210 | Parkinsonian Balance Deficits Quantified Using a Game Industry Board and a Specific Battery of Four Paradigms. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 431.   | 1.0 | 4         |
| 211 | More than a Rumor Spreads in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 608.  | 1.0 | 11        |
| 212 | Alpha-Synuclein Oligomersâ€™ Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. <i>Frontiers in Neuroscience</i> , 2016, 10, 408.  | 1.4 | 288       |
| 213 | Reduced task-related functional connectivity during a set-shifting task in unmedicated early-stage Parkinsonâ€™s disease patients. <i>BMC Neuroscience</i> , 2016, 17, 20.   | 0.8 | 9         |
| 214 | N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data. <i>PLoS ONE</i> , 2016, 11, e0157602.  | 1.1 | 102       |
| 215 | Discriminating among degenerative parkinsonisms using advanced 123 I-ioflupane SPECT analyses. <i>NeuroImage: Clinical</i> , 2016, 12, 234-240.  | 1.4 | 41        |
| 216 | Beware of your Creâ€™Action: <i>lacZ</i> expression impairs neuronal integrity and hippocampusâ€™dependent memory. <i>Hippocampus</i> , 2016, 26, 1250-1264.   | 0.9 | 6         |
| 217 | Merging DBS with viral vector or stem cell implantation: â€œhybridâ€“stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 15051.                              | 1.8 | 14        |
| 218 | FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice. <i>Journal of Biological Chemistry</i> , 2016, 291, 20811-20821.   | 1.6 | 62        |
| 219 | Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the Î±-Synuclein Virus Vectorâ€™Based Parkinson's Disease Mouse Model by Decreasing Î±-Synuclein Oligomeric Species in Mouse Brain. <i>Journal of Neuroscience</i> , 2016, 36, 12485-12497. | 1.7 | 35        |
| 220 | Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2016, 263, 1178-1187.  | 1.8 | 42        |
| 221 | Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. <i>Brain and Behavior</i> , 2016, 6, e00573.   | 1.0 | 79        |
| 222 | Molecular changes in the postmortem parkinsonian brain. <i>Journal of Neurochemistry</i> , 2016, 139, 27-58.   | 2.1 | 74        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 223 | The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease. <i>Journal of Neurochemistry</i> , 2016, 137, 331-359.  | 2.1  | 186       |
| 224 | A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2016, 30, 957-966.   | 2.0  | 1         |
| 225 | The bowel and beyond: the enteric nervous system in neurological disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 517-528.  | 8.2  | 428       |
| 226 | Defects in trafficking bridge Parkinson's disease pathology and genetics. <i>Nature</i> , 2016, 539, 207-216.   | 13.7 | 373       |
| 227 | Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations. <i>Molecular Neurobiology</i> , 2016, 53, 810-817.  | 1.9  | 91        |
| 228 | Î±-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. <i>Human Molecular Genetics</i> , 2016, 25, 1100-1115.  | 1.4  | 45        |
| 229 | Î±-Synuclein aggregation in the olfactory bulb of middle-aged common marmoset. <i>Neuroscience Research</i> , 2016, 106, 55-61.   | 1.0  | 7         |
| 230 | Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 505-513.  | 1.4  | 4         |
| 231 | Anti-Î±-synuclein immunotherapy reduces Î±-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. <i>Acta Neuropathologica Communications</i> , 2017, 5, 7.             | 2.4  | 78        |
| 232 | Improved cognition while cycling in Parkinson's disease patients and healthy adults. <i>Brain and Cognition</i> , 2017, 113, 23-31.   | 0.8  | 20        |
| 233 | Sigma-1 (Î±1) Receptor in Memory and Neurodegenerative Diseases. <i>Handbook of Experimental Pharmacology</i> , 2017, 244, 81-108.  | 0.9  | 43        |
| 234 | What increases the risk of malnutrition in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2017, 375, 235-238.  | 0.3  | 24        |
| 235 | Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3679-E3688. | 3.3  | 122       |
| 236 | Donepezil for Constipation in Lewy Body Diseases: Four Case Studies. <i>Activitas Nervosa Superior</i> , 2017, 59, 19-27.   | 0.4  | 6         |
| 237 | C14orf28 downregulated by miR-519d contributes to oncogenicity and regulates apoptosis and EMT in colorectal cancer. <i>Molecular and Cellular Biochemistry</i> , 2017, 434, 197-208.   | 1.4  | 15        |
| 238 | Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex. <i>Movement Disorders</i> , 2017, 32, 487-497.  | 2.2  | 25        |
| 239 | Comparison of regional cerebral blood flow in Parkinson's disease with depression and major depression. <i>International Journal of Imaging Systems and Technology</i> , 2017, 27, 209-215.   | 2.7  | 2         |
| 240 | Cytokine profiling in the prefrontal cortex of Parkinson's Disease and Multiple System Atrophy patients. <i>Neurobiology of Disease</i> , 2017, 106, 269-278.   | 2.1  | 58        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 241 | Altered Functional and Causal Connectivity of Cerebello-Cortical Circuits between Multiple System Atrophy (Parkinsonian Type) and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 266. | 1.7 | 30        |
| 242 | Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 410.  | 1.7 | 17        |
| 243 | Abnormalities in Structural Covariance of Cortical Gyrfication in Parkinson's Disease. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 12.   | 0.9 | 13        |
| 244 | Reduced CA2-CA3 Hippocampal Subfield Volume Is Related to Depression and Normalized by L-DOPA in Newly Diagnosed Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 84.                            | 1.1 | 26        |
| 245 | PINK1/Parkin-Dependent Mitochondrial Surveillance: From Pleiotropy to Parkinson's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 120.  | 1.4 | 75        |
| 246 | White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1139-1150.  | 2.2 | 11        |
| 247 | Selective $\alpha$ -Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease. <i>Molecular Therapy</i> , 2018, 26, 550-567.                 | 3.7 | 97        |
| 248 | Network connectivity determines cortical thinning in early Parkinson's disease progression. <i>Nature Communications</i> , 2018, 9, 12.   | 5.8 | 198       |
| 249 | High angular resolution diffusion imaging correlates of depression in Parkinson's disease: a connectometry study. <i>Acta Neurologica Belgica</i> , 2018, 118, 573-579.                                       | 0.5 | 9         |
| 250 | Stress-induced changes in miRNA biogenesis and functioning. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 177-191.  | 2.4 | 123       |
| 251 | Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 337-363.                    | 1.4 | 51        |
| 252 | Noninvasive delivery of an $\alpha$ -synuclein gene silencing vector with magnetic resonance-guided focused ultrasound. <i>Movement Disorders</i> , 2018, 33, 1567-1579.                                      | 2.2 | 49        |
| 253 | Insula as the Interface Between Body Awareness and Movement: A Neurofeedback-Guided Kinesthetic Motor Imagery Study in Parkinson's Disease. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 496.           | 1.0 | 26        |
| 254 | The vermiform appendix impacts the risk of developing Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .  | 5.8 | 205       |
| 255 | Tau Pathology in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 809.   | 1.1 | 125       |
| 256 | Hippocampal subfield atrophy in patients with Parkinson's disease and psychosis. <i>Journal of Neural Transmission</i> , 2018, 125, 1361-1372.  | 1.4 | 34        |
| 257 | Blunted cardiovascular responses to exercise in Parkinson's disease patients: role of the muscle metaboreflex. <i>Journal of Neurophysiology</i> , 2018, 120, 1516-1524.                                      | 0.9 | 23        |
| 258 | DnaJ/Hsp40 Family and Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 743.  | 1.4 | 46        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 259 | Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated $\alpha$ -Synuclein Mutant A53T and Affects Locomotor Activity. <i>Frontiers in Neuroscience</i> , 2018, 12, 81.   | 1.4 | 28        |
| 260 | Autophagy Disruptions Associated With Altered Optineurin Expression in Extranigral Regions in a Rotenone Model of Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 289.   | 1.4 | 9         |
| 261 | Role of Plant-Derived Flavonoids and Their Mechanism in Attenuation of Alzheimer's and Parkinson's Diseases: An Update of Recent Data. <i>Molecules</i> , 2018, 23, 814.   | 1.7 | 71        |
| 262 | Current radiotracers to image neurodegenerative diseases. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 17.   | 1.8 | 28        |
| 263 | Development and clinical validation of inertial sensor-based gait-clustering methods in Parkinson's disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2019, 16, 77.   | 2.4 | 19        |
| 264 | The Causative and Curative Roles of Brain-Derived Neurotrophic Factor in Parkinson's Disease. , 0, , .   |     | 0         |
| 265 | Relationship Between Respiratory Sensory Perception, Speech, and Swallow in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 243-249.   | 0.8 | 18        |
| 266 | Ultrasensitive Detection of Aggregated $\alpha$ -Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders. <i>Journal of Neuroimmune Pharmacology</i> , 2019, 14, 423-435.  | 2.1 | 66        |
| 267 | Spreading of $\alpha$ -synuclein – relevant or epiphenomenon?. <i>Journal of Neurochemistry</i> , 2019, 150, 605-611.  | 2.1 | 34        |
| 268 | LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?. <i>Biochemical Society Transactions</i> , 2019, 47, 827-838.  | 1.6 | 15        |
| 270 | Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2224.  | 1.8 | 15        |
| 271 | Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders. <i>Advanced Drug Delivery Reviews</i> , 2019, 148, 181-203.  | 6.6 | 25        |
| 272 | Circulatory responses at the onset of handgrip exercise in patients with Parkinson's disease. <i>Experimental Physiology</i> , 2019, 104, 793-799.   | 0.9 | 10        |
| 273 | Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease. <i>Open Biology</i> , 2019, 9, 180177.  | 1.5 | 59        |
| 274 | The protection capacity of the crude and whole protein spores of <i>Myxobolus koi</i> as an immunostimulant material development in goldfish ( <i>Cyprinus carpio</i> ) for preventing <i>Myxobolus</i> . <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 236, 012084. | 0.2 | 0         |
| 275 | Central control of gastrointestinal motility. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 11-16.   | 1.2 | 27        |
| 276 | Photobiomodulation in Parkinson's disease: A randomized controlled trial. <i>Brain Stimulation</i> , 2019, 12, 810-812.  | 0.7 | 30        |
| 277 | A novel transgenic zebrafish line allows for in vivo quantification of autophagic activity in neurons. <i>Autophagy</i> , 2019, 15, 1322-1332.   | 4.3 | 14        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 278 | Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology. , 0, , .  |     | 0         |
| 279 | VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1272.   | 1.1 | 23        |
| 280 | Cellular and Molecular Mechanisms of Prion Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 497-516.  | 9.6 | 83        |
| 281 | inPentosomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. <i>Journal of Controlled Release</i> , 2019, 294, 17-26.  | 4.8 | 36        |
| 282 | The unlikely partnership between <scp>LRRK</scp>2 and Î±â€synuclein in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2019, 49, 339-363.   | 1.2 | 35        |
| 283 | The application of positron emission tomography (PET) imaging in CNS drug development. <i>Brain Imaging and Behavior</i> , 2019, 13, 354-365.  | 1.1 | 32        |
| 284 | The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. <i>Neurobiology of Disease</i> , 2020, 134, 104614.  | 2.1 | 15        |
| 285 | Pathological changes in the cerebellum of patients with multiple system atrophy and Parkinson's diseaseâ€a stereological study. <i>Brain Pathology</i> , 2020, 30, 576-588.  | 2.1 | 10        |
| 286 | Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopamine-Induced Rat Model of Parkinsonâ€™s Disease is Mediated by Î±7-Nicotinic Receptors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7329. | 1.8 | 41        |
| 287 | Endosomal dysfunction in iPSC-derived neural cells from Parkinsonâ€™s disease patients with VPS35 D620N. <i>Molecular Brain</i> , 2020, 13, 137.   | 1.3 | 16        |
| 288 | Respiratory dysfunction in Parkinson's disease: a narrative review. <i>ERJ Open Research</i> , 2020, 6, 00165-2020.  | 1.1 | 17        |
| 289 | Lateralization of cochlear dysfunction as a specific biomarker of Parkinsonâ€™s disease. <i>Brain Communications</i> , 2020, 2, fcaa144.   | 1.5 | 6         |
| 290 | Endosomal Trafficking in Alzheimer's Disease, Parkinson's Disease, and Neuronal Ceroid Lipofuscinosis. <i>Molecular and Cellular Biology</i> , 2020, 40, .   | 1.1 | 12        |
| 291 | Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinsonâ€™s Disease. <i>Brain Sciences</i> , 2020, 10, 401.   | 1.1 | 18        |
| 292 | Role of RNA Oxidation in Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5022.  | 1.8 | 16        |
| 293 | The Microbiome as a Modifier of Neurodegenerative Disease Risk. <i>Cell Host and Microbe</i> , 2020, 28, 201-222.  | 5.1 | 120       |
| 294 | Role of Insulin in Neurotrauma and Neurodegeneration: A Review. <i>Frontiers in Neuroscience</i> , 2020, 14, 547175.   | 1.4 | 34        |
| 295 | Baroreflex function in Parkinson's disease: insights from the modified-Oxford technique. <i>Journal of Neurophysiology</i> , 2020, 124, 1144-1151.   | 0.9 | 9         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 296 | Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9299.  | 1.8 | 40        |
| 297 | Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 334-343.   | 0.9 | 20        |
| 298 | Evidence of Rehabilitative Impact of Progressive Resistance Training (PRT) Programs in Parkinson Disease: An Umbrella Review. <i>Parkinson's Disease</i> , 2020, 2020, 1-9.  | 0.6 | 6         |
| 299 | Cerebral dopamine neurotrophic factor is essential for enteric neuronal development, maintenance, and regulation of gastrointestinal transit. <i>Journal of Comparative Neurology</i> , 2020, 528, 2420-2444.  | 0.9 | 17        |
| 300 | Modeling Cell-Cell Interactions in Parkinson's Disease Using Human Stem Cell-Based Models. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 571.  | 1.8 | 19        |
| 301 | Parkinson's disease and osteoporosis: basic and clinical implications. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 185-193.   | 1.2 | 11        |
| 302 | Nonpharmacological interventions for respiratory health in Parkinson's disease: A systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2021, 28, 1022-1040.   | 1.7 | 8         |
| 303 | Lewy Body Disease. , 2021, , 18-41.  |     | 0         |
| 304 | Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 11-19. | 1.3 | 16        |
| 305 | Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. <i>Handbook of Clinical Neurology / Edited By P J Vinken and C W Bruyn</i> , 2021, 182, 211-222.             | 1.0 | 3         |
| 306 | Targeting the Mitochondrial Permeability Transition Pore to Prevent Age-Associated Cell Damage and Neurodegeneration. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.   | 1.9 | 40        |
| 307 | Inflammatory Mechanisms in Parkinson's Disease: From Pathogenesis to Targeted Therapies. <i>Neuroscientist</i> , 2022, 28, 485-506.  | 2.6 | 14        |
| 308 | Sexual Disorders and Quality of Life in Parkinson's Disease. <i>Sexual Medicine</i> , 2021, 9, 100280-100280.  | 0.9 | 16        |
| 309 | Yeasts as Complementary Model Systems for the Study of the Pathological Repercussions of Enhanced Synphilin-1 Glycation and Oxidation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1677.  | 1.8 | 1         |
| 310 | The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders. <i>Experimental and Molecular Medicine</i> , 2021, 53, 328-338.   | 3.2 | 54        |
| 311 | Central Neurocircuits Regulating Food Intake in Response to Gut Inputs: Preclinical Evidence. <i>Nutrients</i> , 2021, 13, 908.  | 1.7 | 20        |
| 312 | Autonomic Function in Patients With Parkinson's Disease: From Rest to Exercise. <i>Frontiers in Physiology</i> , 2021, 12, 626640.   | 1.3 | 10        |
| 313 | Baroreflex dysfunction in Parkinson's disease: integration of central and peripheral mechanisms. <i>Journal of Neurophysiology</i> , 2021, 125, 1425-1439.   | 0.9 | 12        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 314 | Neural and Behavioral Evidence for Vibrotactile Beat Perception and Bimodal Enhancement. <i>Journal of Cognitive Neuroscience</i> , 2021, 33, 635-650.   | 1.1 | 3         |
| 315 | Establishing the Rotenone-Induced Parkinson's Disease Animal Model in Wistar Albino Rats. <i>Journal of Health and Allied Sciences NU</i> , 2021, 11, 158-163.   | 0.1 | 0         |
| 316 | Dopamine Transporter Is a Master Regulator of Dopaminergic Neural Network Connectivity. <i>Journal of Neuroscience</i> , 2021, 41, 5453-5470.  | 1.7 | 12        |
| 317 | The effect of subthalamic deep brain stimulation on autonomic dysfunction in Parkinson's disease: clinical and electrophysiological evaluation. <i>Neurological Research</i> , 2021, 43, 894-899.                    | 0.6 | 3         |
| 318 | Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. <i>Frontiers in Neurology</i> , 2021, 12, 681369.   | 1.1 | 10        |
| 319 | The PINK1-Mediated Crosstalk between Neural Cells and the Underlying Link to Parkinson's Disease. <i>Cells</i> , 2021, 10, 1395.   | 1.8 | 6         |
| 320 | The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T $\alpha$ -Synuclein Toxicity in Dopaminergic Neurons In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6760. | 1.8 | 7         |
| 321 | The Role of The Gut Microbiome in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 253-262.   | 1.2 | 7         |
| 322 | Prevalence of malnutrition/malnutrition risk and nutrition-related risk factors among patients with Parkinson's disease: systematic review and meta-analysis. <i>Nutritional Neuroscience</i> , 2022, 25, 2228-2238. | 1.5 | 5         |
| 323 | Physical exercise increases the production of tyrosine hydroxylase and CDF in the spinal cord of a Parkinson's disease mouse model. <i>Neuroscience Letters</i> , 2021, 760, 136089.                                 | 1.0 | 9         |
| 324 | $\alpha$ -Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability. <i>Npj Parkinson's Disease</i> , 2021, 7, 76.  | 2.5 | 14        |
| 325 | Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China. <i>Frontiers in Microbiology</i> , 2021, 12, 728479.   | 1.5 | 13        |
| 326 | A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1555-1567.  | 1.5 | 15        |
| 327 | Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 665820.   | 1.4 | 14        |
| 328 | Color-convertible fluorescent nanoprobe for Parkinson's disease diagnosis. <i>Chemical Engineering Journal</i> , 2022, 429, 132368.  | 6.6 | 6         |
| 330 | Flow Cytometric Evaluation of Crude Synaptosome Preparation as a Way to Study Synaptic Alteration in Neurodegenerative Diseases. <i>Neuromethods</i> , 2018, 141, 297-310.   | 0.2 | 5         |
| 331 | Gastric Dysfunction in Parkinson's Disease. , 2013, , 145-154.   |     | 2         |
| 332 | Recent developments in the pathology of Parkinson's disease. <i>Journal of Neural Transmission Supplementum</i> , 2002, , 347-384.   | 0.5 | 122       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 333 | Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases. <i>International Review of Neurobiology</i> , 2020, 155, 203-234.   | 0.9 | 50        |
| 334 | Depressivität und Depression bei der Parkinson-Erkrankung. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2007, 18, 207-232.  | 0.2 | 1         |
| 336 | Altered cardiorespiratory regulation during exercise in patients with Parkinson's disease: A challenging non-motor feature. <i>SAGE Open Medicine</i> , 2020, 8, 205031212092160.                                 | 0.7 | 19        |
| 337 | Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms. <i>PLoS ONE</i> , 2010, 5, e12728.   | 1.1 | 355       |
| 338 | Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2012, 7, e48783.  | 1.1 | 37        |
| 339 | Abnormal Pulmonary Function and Respiratory Muscle Strength Findings in Chinese Patients with Parkinson's Disease and Multiple System Atrophy—Comparison with Normal Elderly. <i>PLoS ONE</i> , 2014, 9, e116123. | 1.1 | 51        |
| 340 | Analyzing the effectiveness of vocal features in early telediagnosis of Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0182428.  | 1.1 | 73        |
| 341 | Linear and Curvilinear Trajectories of Cortical Loss with Advancing Age and Disease Duration in Parkinson's Disease. , 2016, 7, 220.  |     | 12        |
| 343 | Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson's disease: a Complete Review. , 2017, 1, 001-026.   |     | 8         |
| 344 | Parkinson's Disease: A Review from Pathophysiology to Treatment. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 754-767.  | 1.1 | 103       |
| 345 | Changes of brain gray matter structure in Parkinson's disease patients with dementia. <i>Neural Regeneration Research</i> , 2013, 8, 1276-85.   | 1.6 | 11        |
| 346 | Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy. <i>Frontiers in Neuroscience</i> , 2021, 15, 742065.   | 1.4 | 171       |
| 348 | Die Parkinson-Krankheit. , 2004, , 200-227.   |     | 14        |
| 349 | Presymptomatic and Symptomatic Stages of Intracerebral Inclusion Body Pathology in Idiopathic Parkinson's Disease. , 2005, , 475-502.   |     | 0         |
| 352 | Neurological Sleep Disorders. , 2007, , 271-301.  |     | 0         |
| 353 | Entscheiden bei Morbus Parkinson — eine Übersicht. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2008, 19, 235-251.  | 0.2 | 0         |
| 354 | The Shaking Palsy - Advances in Our Understanding of Parkinson's Disease. <i>Opticon</i> 1826, 2008, , .  | 0.0 | 0         |
| 355 | Pathophysiology of Non-Dopaminergic Monoamine Systems in Parkinson's Disease: Implications for Mood Dysfunction. , 0, , .   |     | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 356 | Chapter 28 Alpha-Synucleinopathy and Neuropsychological Symptoms in a Population-Based Cohort of the Elderly. , 2012, , 309-316.   |     | 0         |
| 357 | Chapter 33 Alpha-Synucleinopathy and Neuropsychological Symptoms in a Population-Based Cohort of the Elderly. , 2013, , 361-368.   |     | 0         |
| 358 | Sleep dysfunction. , 2013, , 120-143.  |     | 0         |
| 359 | Stem Cell Therapy for Neurological Disorders: From Bench to Bedside. , 2014, , 41-70.  |     | 0         |
| 362 | Aging with Parkinsonâ€™s Disease. Handbooks in Health, Work, and Disability, 2018, , 161-174.  | 0.0 | 0         |
| 363 | Cholecalciferol attenuates induced Parkinsonâ€™s like-disease variation and cellular morphology of striatum and substantial Nigra. Anatomy Journal of Africa, 2018, 7, 1258-1273.  | 0.1 | 0         |
| 364 | Lewy Body Disease. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 298-321.  | 0.1 | 0         |
| 366 | Graph Theory on Brain Cortical Sources in Parkinsonâ€™s Disease: The Analysis of â€˜Small Worldâ€™ Organization from EEG. Sensors, 2021, 21, 7266.   | 2.1 | 13        |
| 367 | Basal Ganglia. , 2020, , 591-667.  |     | 2         |
| 368 | Cell therapy in Parkinsonâ€™s disease. Neurotherapeutics, 2004, 1, 382-393.  | 2.1 | 1         |
| 369 | Serotonergic modulation of Neural activities in the entorhinal cortex. International Journal of Physiology, Pathophysiology and Pharmacology, 2012, 4, 201-10.   | 0.8 | 14        |
| 370 | Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P and T, 2015, 40, 504-32.  | 1.0 | 153       |
| 371 | Evaluating a Speech-Specific and a Computerized Step-Training-Specific Rhythmic Intervention in Parkinson's Disease: A Cross-Over, Multi-Arms Parallel Study. Frontiers in Rehabilitation Sciences, 2022, 2, .                   | 0.5 | 1         |
| 373 | Therapeutics in the Pipeline Targeting $\alpha$ -Synuclein for Parkinson's Disease. Pharmacological Reviews, 2022, 74, 207-237.  | 7.1 | 39        |
| 375 | Dysregulation of Human Somatic piRNA Expression in Parkinsonâ€™s Disease Subtypes and Stages. International Journal of Molecular Sciences, 2022, 23, 2469.   | 1.8 | 5         |
| 376 | Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits. Journal of Parkinson's Disease, 2022, 12, 1133-1153. | 1.5 | 8         |
| 377 | Fishing for synucleinopathy models. Fisheries and Aquatic Sciences, 2022, 25, 117-139.   | 0.3 | 0         |
| 378 | A Critical Review of Zebrafish Models of Parkinsonâ€™s Disease. Frontiers in Pharmacology, 2022, 13, 835827.   | 1.6 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | An in vivo Pig Model for Testing Novel Positron Emission Tomography Radioligands Targeting Cerebral Protein Aggregates. <i>Frontiers in Neuroscience</i> , 2022, 16, 847074. | 1.4 | 3         |
| 380 | Activation of $\alpha 7$ nAChR Protects Against Gastric Inflammation and Dysmotility in Parkinson's Disease Rats. <i>Frontiers in Pharmacology</i> , 2021, 12, 793374.       | 1.6 | 7         |
| 381 | Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 838-856.                | 2.9 | 25        |
| 385 | Neuroinflammation in Parkinson's Disease – Putative Pathomechanisms and Targets for Disease-Modification. <i>Frontiers in Immunology</i> , 2022, 13, .                       | 2.2 | 42        |
| 386 | Intranasal Nanoemulsions A Potential Strategy for Targeting The Neurodegenerative Disorder: Parkinson's.. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, . | 0.8 | 0         |
| 387 | Therapeutic Potential of Astrocyte Transplantation. <i>Cell Transplantation</i> , 2022, 31, 096368972211054.   | 1.2 | 13        |
| 388 | $\alpha$ -Synuclein fibril-specific nanobody reduces prion-like $\alpha$ -synuclein spreading in mice. <i>Nature Communications</i> , 2022, 13, .                            | 5.8 | 23        |
| 389 | NF- $\kappa$ B in neurodegenerative diseases: Recent evidence from human genetics. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .                                     | 1.4 | 21        |
| 390 | Imaging the Limbic System in Parkinson's Disease – A Review of Limbic Pathology and Clinical Symptoms. <i>Brain Sciences</i> , 2022, 12, 1248.                               | 1.1 | 13        |
| 391 | Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 1152.                          | 1.7 | 11        |
| 392 | Towards Modern-Age Advanced Sensors for the Management of Neurodegenerative Disorders: Current Status, Challenges and Prospects. , 2022, 1, 042401.                          |     | 32        |
| 393 | Wrist Rigidity Evaluation in Parkinson's Disease: A Scoping Review. <i>Healthcare (Switzerland)</i> , 2022, 10, 2178.  | 1.0 | 2         |
| 394 | The Control Center of Anger. , 2022, , 51-77.  |     | 0         |
| 395 | Neurotoxicity of diesel exhaust extracts in zebrafish and its implications for neurodegenerative disease. <i>Scientific Reports</i> , 2022, 12, .                            | 1.6 | 4         |
| 396 | Parkinson's Disease Detection - An Interpretable Approach to Temporal Audio Classification. , 2022, , .  |     | 2         |
| 397 | Brain modulation by the gut microbiota: From disease to therapy. <i>Journal of Advanced Research</i> , 2023, 53, 153-173.  | 4.4 | 16        |
| 398 | Impairment of functional ability in patients with Parkinson's disease, a qualitative study. , 2022, 22, 48-54.   |     | 0         |
| 399 | Molecular Mechanisms Underlying Neuroinflammation Elicited by Occupational Injuries and Toxicants. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2272.      | 1.8 | 17        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 400 | Early detection of Parkinson's disease using machine learning. <i>Procedia Computer Science</i> , 2023, 218, 249-261.   | 1.2 | 19        |
| 401 | PDGes: An Interpretable Detection Model for Parkinson's Disease Using Smartphones. <i>ACM Transactions on Sensor Networks</i> , 0, , .  | 2.3 | 0         |
| 402 | Translational molecular imaging and drug development in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2023, 18, .   | 4.4 | 11        |
| 403 | A systematic review and meta-analysis of respiratory dysfunction in Parkinson's disease. <i>European Journal of Neurology</i> , 2023, 30, 1481-1504.                                    | 1.7 | 4         |
| 404 | Reduced Range of Gait Speed: A Parkinson's Disease-Specific Symptom?. <i>Journal of Parkinson's Disease</i> , 2023, 13, 197-202.  | 1.5 | 3         |
| 405 | Medical Aid for Parkinson's Patient Experiencing Episodes of Gait Freezing. , 2022, , .   |     | 0         |
| 406 | Gut Microbiota in Autophagy Regulation: New Therapeutic Perspective in Neurodegeneration. <i>Life</i> , 2023, 13, 957.  | 1.1 | 0         |
| 407 | MARS-PD: Meridian Activation Remedy System for Parkinson's Disease. <i>The Journal of Internal Korean Medicine</i> , 2023, 44, 1-11.  | 0.0 | 0         |
| 410 | Diagnosing Methods of Parkinson's Disease. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2023, , 46-63.   | 0.1 | 0         |
| 418 | Evaluation of Machine Learning Techniques for Classification of Early Parkinson's Disease. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2024, , 305-320. | 0.3 | 0         |